Iridex announces a peer-reviewed study confirming MicroPulse TLT's effectiveness and safety in glaucoma treatment over five years.
Quiver AI Summary
Iridex Corporation announced the publication of a significant peer-reviewed study in Ophthalmology Therapy, demonstrating the long-term safety and efficacy of MicroPulse Transscleral Laser Therapy (TLT) in treating primary and secondary glaucoma over five years. Conducted by Dr. Ronald de Crom at the University Eye Clinic Maastricht, the study involved 165 eyes with 112 completing the follow-up. Results indicated a 32.5% average reduction in intraocular pressure and a notable decrease in the need for IOP-lowering medications, with a low complication rate. The findings suggest that MicroPulse TLT could serve as a viable, non-invasive alternative to surgical options, particularly for patients with challenging cases. Iridex's CEO, Patrick Mercer, emphasized the study's role in affirming the company's commitment to innovative glaucoma treatments.
Potential Positives
- The publication of a landmark peer-reviewed study enhances Iridex Corporation's credibility in the ophthalmology market, showcasing the long-term safety and efficacy of its MicroPulse Transscleral Laser Therapy.
- The study's findings indicate significant IOP reduction and low complication rates, positioning MicroPulse TLT as a viable alternative to more invasive glaucoma surgeries, which may expand its market appeal.
- The ability to safely repeat treatments without increasing complication risks emphasizes the long-term viability of Iridex's solution, potentially leading to greater patient and clinician adoption.
- This milestone study supports Iridex's commitment to innovation and improving patient outcomes, which may positively influence investor confidence and market expansion efforts.
Potential Negatives
- The press release contains forward-looking statements that carry inherent risks and uncertainties, indicating that actual results may differ materially from the anticipated outcomes, which may undermine investor confidence.
- The requirement for retreatment in 38% of cases may raise concerns about the long-term viability and effectiveness of the MicroPulse TLT treatment compared to other options.
- The mention of the competitive landscape in glaucoma treatment opens up the possibility of market challenges and pressures, hinting that there may be alternative, possibly more effective treatments available that could affect Iridex's market position.
FAQ
What is MicroPulse Transscleral Laser Therapy?
MicroPulse Transscleral Laser Therapy (TLT) is a laser treatment for managing glaucoma, including both primary and secondary types.
How effective is MicroPulse TLT over five years?
The study indicates that MicroPulse TLT achieved a 32.5% average reduction in intraocular pressure (IOP) over five years with few complications.
Who conducted the landmark study on MicroPulse TLT?
The study was conducted by Dr. Ronald de Crom and colleagues at the University Eye Clinic Maastricht in the Netherlands.
What are the main benefits of MicroPulse TLT?
Main benefits include sustained IOP reduction, minimal complications, and the ability to repeat treatments without invasive surgery risks.
How does Iridex support glaucoma management?
Iridex provides innovative laser-based medical systems that offer effective treatment options for glaucoma, improving patient outcomes and supporting long-term care.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IRIX Hedge Fund Activity
We have seen 8 institutional investors add shares of $IRIX stock to their portfolio, and 11 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AMH EQUITY LTD added 40,321 shares (+8.8%) to their portfolio in Q3 2024
- WOLVERINE TRADING, LLC removed 16,279 shares (-100.0%) from their portfolio in Q2 2024
- CITADEL ADVISORS LLC added 8,918 shares (+21.6%) to their portfolio in Q3 2024
- RENAISSANCE TECHNOLOGIES LLC removed 7,600 shares (-1.9%) from their portfolio in Q3 2024
- UBS GROUP AG added 6,251 shares (+64.8%) to their portfolio in Q3 2024
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 4,530 shares (+7.4%) to their portfolio in Q3 2024
- SIMPLEX TRADING, LLC removed 4,241 shares (-66.2%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
MOUNTAIN VIEW, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced the publication of a landmark peer-reviewed study in
Ophthalmology Therapy
. This study highlights the sustained safety and efficacy of MicroPulse Transscleral Laser Therapy (TLT) (also referred to as Transscleral Cyclophotocoagulation) in managing both primary and secondary glaucoma over five years. Conducted by Dr. Ronald de Crom and colleagues at the University Eye Clinic Maastricht, Netherlands, this research is the first to evaluate outcomes of MicroPulse TLT over such an extended period.
The study assessed 165 pre- and post-cataract eyes treated between 2016 and 2019, with 112 eyes completing the five-year follow-up. Treatment was delivered using the Iridex Cyclo G6® Laser in its MicroPulse® Mode and the original MicroPulse P3® Delivery Device. Results demonstrated that MicroPulse TLT achieved significant (p<0.001) reductions in intraocular pressure (IOP)—32.5% on average—while also enabling a significant reduction (p<0.005) in IOP-lowering medications with a low rate of complications across a broad range of glaucoma types and severities.
"These findings suggest MicroPulse TLT can be a viable alternative to invasive incisional glaucoma surgery, particularly in patients with secondary glaucoma and those for whom incisional surgery may be challenging,” said Dr. de Crom. "Its ability to achieve sustained IOP reduction with minimal complications makes it a cornerstone treatment option."
Additionally, over the five-year follow-up period, only 38% of eyes required retreatment. “Patients who underwent retreatments achieved similar levels of success as those treated initially with no significant increase in complication risk.” Dr. de Crom continued, "The ability to safely repeat MicroPulse treatments while continuing long-term glaucoma care management without having to progress to more invasive glaucoma surgeries, is a huge advantage to clinicians and patients alike!"
Patrick Mercer, CEO of Iridex, commented, "This is the first long-term, peer-reviewed study that demonstrates the safety, effectiveness, and repeatability of MicroPulse TLT. This milestone study supports our commitment to delivering innovative, non-incisional solutions that improve patient outcomes while creating value for our investors and customers.”
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2024 Iridex Corporation. All rights reserved.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning clinical expectations and commercial trends, market adoption and expansion, value-maximizing transactions, demand for and utilization of the Company's products and results and expected sales volumes. The Company can provide no assurance that it will complete any value-maximizing transactions on behalf of its stockholders. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2024. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
Media Contact
Joan Staufer
jstauffer@iridex.com
Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
